| Budget Amount *help |
¥204,230,000 (Direct Cost: ¥157,100,000、Indirect Cost: ¥47,130,000)
Fiscal Year 2021: ¥37,830,000 (Direct Cost: ¥29,100,000、Indirect Cost: ¥8,730,000)
Fiscal Year 2020: ¥36,400,000 (Direct Cost: ¥28,000,000、Indirect Cost: ¥8,400,000)
Fiscal Year 2019: ¥38,610,000 (Direct Cost: ¥29,700,000、Indirect Cost: ¥8,910,000)
Fiscal Year 2018: ¥46,280,000 (Direct Cost: ¥35,600,000、Indirect Cost: ¥10,680,000)
Fiscal Year 2017: ¥45,110,000 (Direct Cost: ¥34,700,000、Indirect Cost: ¥10,410,000)
|
|---|
| Outline of Final Research Achievements |
I conducted the functional analyses of LUBAC ubiquitin ligase, which is the only enzyme that produces the same chain as the linear ubiquitin chain discovered by the principal investigator, and its development into diseases. I elucidated the mechanism of regulation of LUBAC activity and showed that its hyperactivity can suppress immunodeficiency and autoinflammatory diseases. Furthermore, we clarified the pathogenic mechanism of lymphoma due to the enhanced function of LUBAC, the role of linear ubiquitin chains in immune system cells, and the abnormal glycogen metabolism due to HOIL-1L subunit abnormality. In addition, it has been clarified that the enhancement of LUBAC function contributes to the onset of systemic lupus erythematosus.
|
